Patents by Inventor Atsuo TANIMOTO
Atsuo TANIMOTO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240075037Abstract: [PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor. [SOLUTION MEANS] A therapeutic or preventive agent for a skin disease selected from the group consisting of senile xerosis, asteatosis, eczema and contact dermatitis, containing a JAK inhibitor as an active ingredient. [EFFECT] The followings are found: a JAK inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and ?-defensin 3 as skin barrier function-related proteins; a JAK inhibitor significantly increases NMF production in a Tape Stripping-treated mouse; and a JAK inhibitor significantly accelerates a reduction in TEWL in a dry skin mouse model, namely improves the skin barrier function. The JAK inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, type B peeling skin syndrome, etc.Type: ApplicationFiled: February 1, 2023Publication date: March 7, 2024Applicants: Japan Tobacco Inc., Kyoto UniversityInventors: Atsuo TANIMOTO, Yoshifumi UEDA, Yukari KIMOTO (formerly KITAO), Wataru AMANO, Kenji KABASHIMA
-
Publication number: 20220088020Abstract: The present invention provides a novel treatment of alopecia areate. The problem to be solved by the invention is to provide a new pharmaceutical use of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile. A therapeutic or preventive agent for alopecia areata, containing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile as an active ingredient.Type: ApplicationFiled: April 13, 2021Publication date: March 24, 2022Inventors: Michael SIERRA, Tord LABUDA, Atsuo TANIMOTO, Yuichi SHINOZAKI
-
Publication number: 20210205308Abstract: [PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor. [SOLUTION MEANS] A therapeutic or preventive agent for a skin disease selected from the group consisting of senile xerosis, asteatosis, eczema and contact dermatitis, containing a JAK inhibitor as an active ingredient. [EFFECT] The followings are found: a JAK inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and ?-defensin 3 as skin barrier function-related proteins; a JAK inhibitor significantly increases NMF production in a Tape Stripping-treated mouse; and a JAK inhibitor significantly accelerates a reduction in TEWL in a dry skin mouse model, namely improves the skin barrier function. The JAK inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, type B peeling skin syndrome, etc.Type: ApplicationFiled: August 12, 2020Publication date: July 8, 2021Applicants: Japan Tobacco Inc., Kyoto UniversityInventors: Atsuo TANIMOTO, Yoshifumi UEDA, Yukari KIMOTO (formerly KITAO), Wataru AMANO, Kenji KABASHIMA
-
Publication number: 20190262344Abstract: The invention provides a method for treating or preventing a skin disease, such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, and type B peeling skin syndrome, by administering an effective amount of a JAK inhibitor to a mammal in need thereof. The invention also provides methods of improving skin barrier function, increasing transcription of a gene, and increasing production of a protein in a mammal by administering an effective amount of a JAK inhibitor to the mammal.Type: ApplicationFiled: October 3, 2018Publication date: August 29, 2019Applicants: Japan Tobacco Inc., Kyoto UniversityInventors: Atsuo TANIMOTO, Yoshifumi UEDA, Yukari KIMOTO (formerly KITAO), Wataru AMANO, Kenji KABASHIMA
-
Publication number: 20180263986Abstract: The present invention provides a novel treatment of alopecia areate. The problem to be solved by the invention is to provide a new pharmaceutical use of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile. A therapeutic or preventive agent for alopecia areata, containing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile as an active ingredient.Type: ApplicationFiled: September 22, 2016Publication date: September 20, 2018Applicants: LEO Pharma A/S, Japan Tobacco Inc.Inventors: Michael SIERRA, Tord LABUDA, Atsuo TANIMOTO, Yuichi SHINOZAKI
-
Publication number: 20170035763Abstract: [PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor. [SOLUTION MEANS] A therapeutic or preventive agent for a skin disease selected from the group consisting of senile xerosis, asteatosis, eczema and contact dermatitis, containing a JAK inhibitor as an active ingredient. [EFFECT] The followings are found: a JAK inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and ?-defensin 3 as skin barrier function-related proteins; a JAK inhibitor significantly increases NMF production in a Tape Stripping-treated mouse; and a JAK inhibitor significantly accelerates a reduction in TEWL in a dry skin mouse model, namely improves the skin barrier function. The JAK inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, type B peeling skin syndrome, etc.Type: ApplicationFiled: March 16, 2016Publication date: February 9, 2017Applicants: Japan Tobacco Inc., Kyoto UniversityInventors: Atsuo TANIMOTO, Yoshifumi UEDA, Yukari KIMOTO (formerly KITAO), Wataru AMANO, Kenji KABASHIMA
-
Publication number: 20140343034Abstract: [PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor. [SOLUTION MEANS] A therapeutic or preventive agent for a skin disease selected from the group consisting of senile xerosis, asteatosis, eczema and contact dermatitis, containing a JAK inhibitor as an active ingredient. [EFFECT] The followings are found: a JAK inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and ?-defensin 3 as skin barrier function-related proteins; a JAK inhibitor significantly increases NMF production in a Tape Stripping-treated mouse; and a JAK inhibitor significantly accelerates a reduction in TEWL in a dry skin mouse model, namely improves the skin barrier function. The JAK inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, type B peeling skin syndrome, etc.Type: ApplicationFiled: April 23, 2014Publication date: November 20, 2014Applicants: Japan Tobacco Inc., Kyoto UniversityInventors: Atsuo TANIMOTO, Yoshifumi UEDA, Yukari KIMOTO (formerly KITAO), Wataru AMANO, Kenji KABASHIMA